Related Experiment Video
Updated: Apr 7, 2026
Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues
Published on: July 8, 2020
Antiproliferative Effect of Rottlerin on Sk-Mel-28 Melanoma Cells
Elena Daveri1, Giuseppe Valacchi2, Roberta Romagnoli1
1Department of Life Sciences, University of Siena, Via Aldo Moro 7, 53100 Siena, Italy.
Abstract:
Melanoma is the most aggressive and chemoresistant form of skin cancer. Mutated, constitutively active B-RAF is believed to play a crucial role, although the selective B-RAF inhibition has shown poor clinical success, since phenomena of resistance usually occur, likely arising from additional genetic aberrations, such as loss of function of p53 and PTEN, overexpression of cyclin D1, hyperactivation of NF-κB, and downregulation of p21/Cip1. Since all of them are present in the Sk-Mel-28 melanoma cells, this cell line could be an ideal, albeit hard to study, model to develop new therapeutic strategies. In the current study, we tested the cytostatic action of Rottlerin on Sk-Mel-28 melanoma cells, on the basis of the known Rottlerin effects on the main proliferative signaling pathways. We presented evidence that the drug inhibits cell growth by an Akt- and p21/Cip1-independent mechanism, involving the dual inhibition of ERK and NF-κB and downregulation of cyclin D1. In addition, we found that Rottlerin increases ERK phosphorylation, but, surprisingly, this resulted in decreased ERK activity. Pull-down experiments, using Rottlerin-CNBr-conjugated Sepharose beads, revealed that Rottlerin binds to ERK, independently from its phosphorylation status. This direct interaction could in part explain the paradoxical blockage of ERK downstream signaling and growth arrest. We would like to dedicate this paper to the memory of our friend and colleague, prematurely deceased, Claudia Torricelli, who actively contributed to this project.
Insights
Rottlerin effectively inhibits melanoma cell growth by targeting ERK and NF-κB pathways, independent of Akt and p21. This novel therapeutic strategy shows promise for chemoresistant melanoma.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Melanoma is an aggressive skin cancer known for chemoresistance.
- Resistance to targeted therapies like B-RAF inhibitors often involves genetic aberrations such as p53/PTEN loss, cyclin D1 overexpression, NF-κB hyperactivation, and p21/Cip1 downregulation.
- The Sk-Mel-28 melanoma cell line exhibits these resistance mechanisms, making it a valuable model for studying new therapeutic strategies.
Purpose of the Study:
- To investigate the cytostatic effects of Rottlerin on Sk-Mel-28 melanoma cells.
- To elucidate the molecular mechanisms underlying Rottlerin's action, focusing on key proliferative signaling pathways.
Main Methods:
- Treatment of Sk-Mel-28 cells with Rottlerin.
- Analysis of cell growth inhibition.
- Assessment of signaling pathway modulation, including Akt, p21/Cip1, ERK, NF-κB, and cyclin D1.
- Investigation of Rottlerin's direct interaction with ERK using pull-down assays with Rottlerin-CNBr-conjugated Sepharose beads.
Main Results:
- Rottlerin demonstrated cytostatic action on Sk-Mel-28 cells.
- Inhibition of cell growth occurred through an Akt- and p21/Cip1-independent mechanism.
- Rottlerin induced dual inhibition of ERK and NF-κB signaling pathways.
- Downregulation of cyclin D1 was observed.
- Rottlerin increased ERK phosphorylation, paradoxically leading to decreased ERK activity.
- Direct binding of Rottlerin to ERK was confirmed, irrespective of its phosphorylation status.
Conclusions:
- Rottlerin exhibits anti-proliferative effects on chemoresistant melanoma cells.
- The mechanism involves direct interaction with ERK, leading to its functional inhibition, alongside NF-κB inhibition and cyclin D1 downregulation.
- Rottlerin represents a potential therapeutic agent for melanoma, particularly in cases of resistance to conventional therapies.
